Aurobindo Pharma Ltd said its wholly owned unit Auro Pharma Ltd has acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories Pvt. Ltd. on a going-concern basis for ₹325 crore in cash.
The company said the acquisition was completed through a Business Transfer Agreement and is effective from January 1, 2026. The acquired business comprises 23 brands marketed across 67 SKUs and nine pipeline products, with key portfolios in anti-infectives and pain management.
The business employs about 470 field staff and has a distribution network of more than 1,600 stockists and related infrastructure. In FY2024-25 the business reported turnover of ₹1,135.3 million and EBITDA of ₹289.9 million, according to the exchange filing.
Founded in 1973–74, Khandelwal Laboratories operates in India and specializes in branded oncology and non-oncology prescription formulations. Auro Pharma said the acquisition will strengthen its presence in the domestic pharmaceutical market and complement its existing pain management and anti-infective portfolios.
Auro Pharma management said the deal will enhance the company’s growth prospects and expand its range of prescription offerings in the domestic market.
Shares of Aurobindo Pharma ended higher on Thursday, January 1, rising 1.18% to ₹1,197.00 on the NSE.
Leave a Reply